Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia

References

• Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123(20), 2292–2333 (2011).
   Google Scholar
• National Cholesterol Education Program Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002).
   Google Scholar
• Athyros VG, Giouleme OI, Nikolaidis NL et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J. Clin. Gastroenterol. 34(4), 472–475 (2002).
   Google Scholar
• Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J. Clin. Gastroenterol. 36(1), 54–62 (2003).
   Google Scholar
• Assmann, G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 77(14), 1179–1184 (1996).
   Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 115(4), 450–458 (2007).
   Google Scholar
• Hokanson, JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 3(2), 213–219 (1996).
   Google Scholar
• Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18), 1993–2000 (2009).
   Google Scholar
• Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375(9726), 1634–1639 (2010).
   Google Scholar
• Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J. Clin. Lipidol. 6(5), 413–426 (2012). • Review of treatment strategies for patients with hypertriglyceridemia.
   Google Scholar
• Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 106(16), 2137–2142 (2002).
   Google Scholar
• Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 176(8), 1113–1120 (2007).
   Google Scholar
• Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 35(1), 1–10 (2000).
   Google Scholar
• Bays HE, Tighe AP, Sadovsky R, Davidon MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc. Ther. 6(3), 391–409 (2008).
   Google Scholar
• Schima SM, Maciejewski SR, Hilleman DE, Williams MA, Mohiuddon SM. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opin. Pharmacother. 11(5), 731–738 (2010).
   Google Scholar
• Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and Type 2 diabetes mellitus. Expert Opin. Pharmacother. 12(9), 1429–1438 (2011).
   Google Scholar
• Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 375(9729), 1875–1884 (2010).
   Google Scholar
• ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563–1574 (2010).
   Google Scholar
• Saito Y, Yokoyama M, Origasa H et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200(1), 135–140 (2008).
   Google Scholar
• Scott R, O’Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 32(3), 493–498 (2009).
   Google Scholar
• AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011).
   Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza Nell’Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. results of the GISSI-Prevenzione trial. Lancet 354(9177), 447–455 (1999).
   Google Scholar
• Lawson LD, Hughes BG. Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters. Biochem. Biophys. Res. Commun. 152(1), 328–335 (1988).
   Google Scholar
• Beckermann B, Beneke BM, Seitz I. Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers. Arzneimittelforschung 40(6), 700–704 (1990).
   Google Scholar
• Feagan BG, Sandborn WJ, Mittmann U et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA 299(14), 1690–1697 (2008).
   Google Scholar
• Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova® compared with Lovaza® in a pharmacokinetic single-dose evaluation) study. J. Clin. Lipidol. 6(6). 573–584 (2012). •• Demonstrated the markedly improved bioavailability of OM3-CA over OM3-EE following a single dose.
   Google Scholar
• Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Migliolo M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N. Engl. J. Med. 334(24), 1557–1560 (1996).
   Google Scholar
• Offman E, Marenco T, Ferber S et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc. Health. Risk Manag. 9, 563–573 (2013). •• Demonstrated enhanced bioavailability of OM3-CA over OM3-EE following daily dosing for 2 weeks.
   Google Scholar
• Kastelein JJ, Maki KC, Susekov A et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the Epanova For Lowering Very High Triglycerides (EVOLVE) trial. J. Clin. Lipidol. 8(1), 94–106 (2014). •• Demonstrated the tg-lowering efficacy of OM3-CA in patients with severe hypertriglyceridemia.
   Google Scholar
• Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr. Atheroscler. Rep. 13(6), 474–483 (2011).
   Google Scholar
• Maki KC, Orloff DG, Nicholls SJ et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin. Ther. 35(9), 1400–1411 e1–e3 (2013). •• Demonstrated the TG-altering efficacy of OM3-CA in hypertriglyceridemic patients on statin therapy.
   Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-Center, Placebo-Controlled, Randomized, Double-blind, 12-Week Study with an Open-Label Extension [MARINE] trial). Am. J. Cardiol. 108(5), 682–690 (2011).
   Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 110(7), 984–992 (2012).
   Google Scholar
• Hiatt WR, Smith RJ. Assessing the clinical benefits of lipid-disorder drugs. N. Engl. J. Med. 370(5), 396–399 (2014).
   Google Scholar
• Omthera Pharmaceuticals (2014). www.omthera.com/epanova_overview.html
   Google Scholar
• US FDA (2014). www.accessdata.fda.gov/drugsatfda_docs/label/2009/021654s023lbl.pdf
   Google Scholar
• US FDA (2014). www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202057Orig1s000Approv.pdf
   Google Scholar
• GlaxoSmithKline (2014). http://us.gsk.com/products/assets/us_lovaza.pdf
   Google Scholar
• Vascepa (2014). www.vascepa.com/full-prescribing-information.pdf
   Google Scholar
• Teva Pharmaceuticals Industry Ltd. (2014). www.tevapharm.com/Media/News/Pages/2014/1916694.aspx
   Google Scholar
• US FDA (2014). www.accessdata.fda.gov/drugsatfda_docs/label/2014/204977s000lbl.pdf
   Google Scholar
• US FDA (2014). www.fda.gov/siteindex/ucm108351.htm
   Google Scholar
• AstraZeneca (2014). www1.astrazeneca-us.com/pi/epanova.pdf
   Google Scholar